New pharmaceutical products face many potential hurdles to commercial success including regulatory approval, national and regional market access, and physician and patient acceptance and uptake, to name a few. Each stage of the development cycle involves an ever-widening group of stakeholders. Securing the buy-in of these influential external stakeholders requires pharmaceutical companies to look inward and encourage cross-functional collaboration and the ability to engage early, and often, along the path to launch and beyond. To read more, click the link below.
NCDs & long-term antimicrobial therapy
1 in 4 people globally are already affected by NCDs. By 2030, NCDs will cause 55 million deaths per year under ‘business as usual.’1,2 Effective...